Compare GRNT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRNT | MNPR |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.7M | 587.4M |
| IPO Year | 2022 | 2019 |
| Metric | GRNT | MNPR |
|---|---|---|
| Price | $5.03 | $114.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $6.00 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 800.2K | 230.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | 28.57 | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $32.77 |
| 52 Week High | $6.15 | $124.82 |
| Indicator | GRNT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 53.18 |
| Support Level | $4.83 | $102.88 |
| Resistance Level | $5.05 | $114.60 |
| Average True Range (ATR) | 0.14 | 6.75 |
| MACD | -0.02 | -1.31 |
| Stochastic Oscillator | 28.13 | 46.44 |
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.